Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012 Financial Results on Thursday, March 7, 2013

 Simcere Pharmaceutical Group to Announce Fourth Quarter and Fiscal Year 2012
                 Financial Results on Thursday, March 7, 2013

PR Newswire

NANJING, China, Feb. 25, 2013

NANJING, China, Feb. 25, 2013 /PRNewswire/-- Simcere Pharmaceutical Group
(NYSE: SCR), a leading pharmaceutical company specializing in the development,
manufacturing, and marketing of branded generic and proprietary
pharmaceuticals in China, today announced that it will report its unaudited
financial results for the fourth quarter and fiscal year ended December 31,
2012 on Thursday, March 7, 2013, before the market opens in the United States.
Simcere's management will host an earnings conference call on the same day at
8 a.m. ET (Thursday, March 7 at 9 p.m. Beijing/Hong Kong time).

To access the conference call, please dial:

International toll:            +65.6723.9381
United States toll-free:   +1.866.519.4004
United States toll:           +1.718.354.1231
China Domestic toll-free:                800.819.0121
China Domestic mobile toll-free:                     400.620.8038
Hong Kong toll:           +852.2475.0994

Please ask to be connected to Q4 2012 Simcere Pharmaceutical Group Earnings
Conference Call and provide the following passcode: 12783585.

Simcere will also broadcast a live audio webcast of the conference call. The
broadcast will be available by visiting the "Investor Relations" section of
the company's web site at www.simcere.com.

Following the earnings conference call, an archive of the call will be
available by dialing:

United States toll-free:    +1.855.452.5696
United States toll:  +1.646.254.3697

The passcode for replay participants is 12783585. The telephone replay also
will be archived on the "Investor Relations" section of the company's website
for seven days following the earnings announcement.

About Simcere Pharmaceutical Group

Simcere Pharmaceutical Group (NYSE:SCR, Simcere) is a leading pharmaceutical
company specializing in the development, manufacturing, and marketing of
branded and proprietary pharmaceuticals in China. Simcere concentrates its
research and development efforts on the treatment of diseases with high
incidence and/or mortality rates and for which there is a clear demand for
more effective pharmacotherapy such as cancer, strokes, cardiovascular
disease, infectious diseases and pain. For more information about Simcere
Pharmaceutical Group, please visit www.simcere.com.

Investor and Media Contacts:
Email: ir@simcere.com

In Nanjing:                    In the United States:
Jie Liu D'Elia                 Cindy Zheng
Vice President                 Brunswick Group
Simcere Pharmaceutical Group   Tel: 1-212-333-3810
Tel: 86-25-8556-6666*8857
In Beijing:
Yue Yu
Brunswick Group
Tel: 86-10-5960-8600



SOURCE Simcere Pharmaceutical Group

Website: http://www.simcere.com
 
Press spacebar to pause and continue. Press esc to stop.